Maqola

Renal denervation in the antihypertensive arsenal – knowns and known unknowns

Franz H. MesserliDepartment of BioMedical Research, University of Bern, Bern, SwitzerlandChirag BavishiDepartment of Cardiology, University of Missouri, Columbia, Missouri, USAJana BrguljanUniversity Medical Centre Ljubljana, Department of Hypertension, Medical University Ljubljana, SloveniaMichel BurnierUniversity of Lausanne. Faculty of Biology and Medicine, Lausanne, SwitzerlandStephan DobnerDepartment of Cardiology, Bern University Hospital University of Bern, Bern, SwitzerlandFernando ElijovichDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University, USAKeith C. FerdinandTulane University School of Medicine, New Orleans, Los Angeles, USASverre E. KjeldsenDepartment of Cardiology, University of Oslo Hospital, Oslo, NorwayCheryl L. LafferDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee, USAC. Venkata S. RamApollo Hospitals and Medical College, Hyderabad, Telangana, IndiaEmrush RexhajDepartment of BioMedical Research, University of Bern, Bern, SwitzerlandLuís M. RuilopeCardiorenal Translational Laboratory and Hypertension Unit, Institute of Research i+12, CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, SpainE. ShalaevaDepartment of Cardiology, Tashkent Medical Academy, Tashkent, UzbekistanGeorge C.M. SiontisDepartment of Cardiology, Bern University Hospital, University of Bern, Bern, SwitzerlandJan A. StaessenStephen C. TextorDivision of Hypertension and Nephrology, Mayo Clinic, Rochester, Minnesota, USAWanpen VongpatanasinHypertension Section, Cardiology Division, University of Texas Southwestern Medical Center, Dallas, Texas, USALiffert VogtDepartment of Internal Medicine, section Nephrology, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, Amsterdam, The NetherlandsMassimo VolpeDepartment of Clinical and Molecular Medicine, University of Rome Sapienza, Rome, ItalyJi‐Guang WangThe Shanghai Institute of Hypertension, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, ChinaBryan WilliamsInstitute of Cardiovascular Science, University College London, London, United Kingdom

Journal of Hypertensionjournal2022en

ABI

Annotatsiya

Even though it has been more than a decade since renal denervation (RDN) was first used to treat hypertension and an intense effort on researching this therapy has been made, it is still not clear how RDN fits into the antihypertensive arsenal. There is no question that RDN lowers blood pressure (BP), it does so to an extent at best corresponding to one antihypertensive drug. The procedure has an excellent safety record. However, it remains clinically impossible to predict whose BP responds to RDN and whose does not. Long-term efficacy data on BP reduction are still unconvincing despite the recent results in the SPYRAL HTN-ON MED trial; experimental studies indicate that reinnervation is occurring after RDN. Although BP is an acceptable surrogate endpoint, there is complete lack of outcome data with RDN. Clear indications for RDN are lacking although patients with resistant hypertension, those with documented increase in activity of the sympathetic system and perhaps those who desire to take fewest medication may be considered.

Hali tarjima qilinmagan

Mavzular

Blood Pressure and Hypertension Studies Migraine and Headache Studies Cardiovascular Syncope and Autonomic Disorders

Identifikatorlar

DOI: 10.1097/hjh.0000000000003171

Iqtiboslar va manbalar

3 ta iqtibos 145 ta foydalanilgan manba

Koʻrsatkichlar — AkademScholar